Erratum: CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study

The January 1, 2023 article by You et al entitled “CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study” (J Clin Oncol 10.1200/JCO.22.00430) was published with errors.

In Figure 3, in both parts A and B, the labels that read non-HRP should have read as: HRP

This has been corrected as of January 25, 2023. The authors apologize for the errors.